Open AccessTrends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010
Author(s) -
Joseph S. Ross,
Sharon Glave Frazee,
Susan B. Garavaglia,
Rebecca Levin,
Haik Novshadian,
Cynthia A. Jackevicius,
Glen Stettin,
Harlan M. Krumholz
Publication year - 2014
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2014.3404
Subject(s) - ezetimibe , medicine , discontinuation , simvastatin , medical prescription , pharmacy , cholesterol , statin , pharmacology , family medicine
Results from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial, announced in January 2008, demonstrated that ezetimibe use lowered cholesterol levels but did not slow the progression of atherosclerosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom